<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>Evidence-Based Medicine: Core Concepts and Study Designs</title>
    <meta charset="utf-8" />
    <meta name="author" content="Austin Meyer, MD, PhD, MS, MPH, MS, FAAP, etc." />
    <meta name="date" content="2025-06-13" />
    <script src="libs/header-attrs-2.27/header-attrs.js"></script>
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

.title[
# Evidence-Based Medicine: Core Concepts and Study Designs
]
.author[
### Austin Meyer, MD, PhD, MS, MPH, MS, FAAP, etc.
]
.date[
### June 13, 2025
]

---




class: middle, center, inverse

# Evidence-Based Medicine: Core Concepts and Study Designs

### A Lecture for Pediatric Residents

---

class: middle

# Agenda: Part 1 - Statistics &amp; Measures

.pull-left[
**Session Overview:**
1. **Introduction to EBM** - 5 min
2. **Basic Statistical Terms** - 10 min  
3. **Accuracy vs Precision** - 5 min
4. **Statistical Inference** - 15 min
5. **Hypothesis Testing** - 15 min
6. **Clinical Metrics** - 20 min
7. **Important Caveats** - 10 min
]

.pull-right[
**Part 2 Preview:**
1. **Key Concepts Review** - 5 min
2. **Types of Biases** - 15 min
3. **Study Designs** - 25 min
4. **Study Limitations** - 15 min
5. **Q&amp;A** - 5 min
]

---

class: middle, center

# Basic Statistical Terms

---

class: middle

# Generalizability (External Validity)

.pull-left[
**Definition:** How applicable are findings from a study sample to the broader population?

**Key Question:** Can you apply these results to YOUR patients in YOUR clinical setting?
]

.pull-right[
**Clinical Example:**
- Study: New asthma medication tested in highly controlled, homogeneous population
- Your patients: Diverse demographics, varying comorbidities, different severities
- **Question:** Are the findings generalizable?
]

---

class: middle

# P-value: What It Actually Means

.pull-left[
**Definition:** Probability of observing results this extreme (or more extreme) **IF the null hypothesis is true**

**What p &lt; 0.05 means:**
- IF there's truly no effect
- THEN there's &lt; 5% chance of seeing this result
- We reject "no effect" hypothesis
]

.pull-right[
**Common Misconceptions:**
- ❌ 5% chance null hypothesis is true
- ❌ 95% chance alternative is true  
- ❌ Probability result was due to chance

**Correct Interpretation:**
- ✅ Evidence against null hypothesis
- ✅ Statistical significance at α = 0.05
]

---

class: middle

# Confidence Interval (CI)

.pull-left[
**Definition:** Range of plausible values for the true population parameter

**95% CI Interpretation:**
- If we repeated the study many times
- 95% of calculated CIs would contain the true value
- Provides precision estimate
]

.pull-right[
**Relationship to P-value:**
- For differences: CI excluding 0 → p &lt; 0.05
- For ratios: CI excluding 1 → p &lt; 0.05
- Wider CI = less precision
- Narrower CI = more precision
]

---

class: middle

# Efficacy vs Effectiveness

.pull-left[
### Efficacy
**"Can it work?"**
- Ideal conditions
- Controlled settings
- High adherence
- Selected patients
- RCT environment
]

.pull-right[
### Effectiveness  
**"Does it work in practice?"**
- Real-world conditions
- Routine clinical practice
- Variable adherence
- Diverse patients
- Practical constraints
]

---

class: middle, center

# Accuracy and Precision

---

class: middle, center

# Visual Reminder: Accuracy vs Precision

&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/precision-accuracy-1.png" width="60%" style="display: block; margin: auto;" /&gt;

---

class: middle

# Accuracy vs Precision Definitions

.pull-left[
**Accuracy**
- How close to the TRUE value
- Think: hitting the bullseye
- Threatened by **bias** (systematic error)
- Results close to reality
]

.pull-right[
**Precision**
- How consistent/reproducible
- Think: tight grouping of shots
- Threatened by **random error** (small sample)
- Narrow confidence intervals
]

---

class: middle, center

# Statistical Inference &amp; Distributions

---

class: middle

# Distribution Properties Matter

.pull-left[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/normal-dist-1.png" width="100%" style="display: block; margin: auto;" /&gt;
]

.pull-right[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/t-dist-1.png" width="100%" style="display: block; margin: auto;" /&gt;
]

---

class: middle

# Real Data Can Be Complex

.pull-left[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/unimodal-1.png" width="100%" style="display: block; margin: auto;" /&gt;

**Single peak** - homogeneous population
]

.pull-right[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/bimodal-1.png" width="100%" style="display: block; margin: auto;" /&gt;

**Two peaks** - distinct subgroups
]

---

class: middle

# Skewed Distributions: Order Matters

.pull-left[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/right-skew-1.png" width="100%" style="display: block; margin: auto;" /&gt;
]

.pull-right[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/left-skew-1.png" width="100%" style="display: block; margin: auto;" /&gt;
]

---

class: middle

# Quick Quiz: Skewed Distribution

.pull-left[
**Which order (left to right) for Right Skewed?**

A. mean, median, mode  
B. mode, mean, median  
C. median, mode, mean  
D. **mode, median, mean**  
E. mean, mode, median

**Remember:** Tail direction = skew direction
]

.pull-right[
&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/quiz-plot-1.png" width="100%" style="display: block; margin: auto;" /&gt;
]

---

class: middle, center

# Hypothesis Testing

---

class: middle

# Statistical Tests by Data Type

.pull-left[
**Categorical Data (Counts)**
- **Chi-square test:** 2+ categorical variables
- **Fisher exact test:** 2×2 tables, small cells
- *Example:* Vaccination status vs disease outcome

**Quantitative + Groups**
- **T-test:** Compare 2 group means
  - *Paired:* Before/after same subjects
  - *Independent:* Different groups
- **Mann-Whitney U:** Non-parametric alternative
- **ANOVA:** Compare 3+ group means
]

.pull-right[
**Ordinal Data (Ranked)**
- **Spearman correlation:** Monotonic relationships
- *Example:* Disease severity (mild/moderate/severe) vs pain score

**Two Quantitative Variables**
- **Pearson correlation:** Linear relationships
- *Example:* Age vs height in children
]

---

class: middle, center

# Question

.pull-left[
**Table 1: OCP Use and Blood Clots**

| | Clot | No Clot | Total |
|---|---:|---:|---:|
| **OCP Use** | 500 | 400 | 900 |
| **No OCP Use** | 80 | 20 | 100 |
| **Total** | 580 | 420 | 1000 |
]

.pull-right[
**Best method to assess association?**

A. Two sample T-test  
B. Analysis of variance  
C. Pearson correlation  
D. Chi-square test
E. Spearman correlation
]

---

class: middle, center

# Question

.pull-left[
**Table 1: OCP Use and Blood Clots**

| | Clot | No Clot | Total |
|---|---:|---:|---:|
| **OCP Use** | 500 | 400 | 900 |
| **No OCP Use** | 80 | 20 | 100 |
| **Total** | 580 | 420 | 1000 |
]

.pull-right[
**Best method to assess association?**

A. Two sample T-test  
B. Analysis of variance  
C. Pearson correlation  
D. **Chi-square test** ✓  
E. Spearman correlation

**Why Chi-square?** Two categorical variables (OCP: Yes/No, Clot: Yes/No)
]

---

class: middle

# Hypothesis Testing Framework

.pull-left[
**Null Hypothesis (H₀)**
- Default assumption
- "No effect," "no difference," "no relationship"
- What we test against

**Alternative Hypothesis (H₁)**
- What we want to demonstrate
- "There IS an effect/difference/relationship"
- Never "proven," only supported
]

.pull-right[
**Decision Rules**
- **Reject H₀ if p &lt; 0.05** (typical)
- For ratios: 95% CI not including 1
- For differences: 95% CI not including 0

**Board Exam Tip:** Assume H₀ rejected when p &lt; 0.05
]

---

class: middle

# Four Possible Outcomes

.center[
| | H₀ True | H₀ False |
|---|---|---|
| **Reject H₀** | Type I Error (α) | Correct ✓ |
| **Fail to Reject H₀** | Correct ✓ | Type II Error (β) |
]

.pull-left[
**Type I Error (α = False Positive)**
- Conclude effect when none exists
- Usually set at 5%

**Power (1-β)**
- Probability of detecting true effect
- Increases with sample size
]

.pull-right[
**Type II Error (β = False Negative)**  
- Miss a real effect
- Often due to small sample

**Key Point:** Bigger sample = More power
]

---

class: middle, center

# Clinical/Epidemiological Metrics

---

class: middle

# Essential Metrics You Must Know

.pull-left[
### The Big Four
1. **Odds Ratio (OR)**
2. **Risk Ratio (RR)**  
3. **Risk Difference (RD)**
4. **Number Needed to Treat (NNT)**
]

.pull-right[
### When to Use Each
- **OR:** Case-control studies, rare diseases
- **RR:** Cohort studies, RCTs  
- **RD:** When absolute risk matters
- **NNT:** Clinical decision-making
]

---

class: middle, center

# Sample Data for Calculations

&lt;img src="Evidence-Based-Medicine---Part-3_files/figure-html/sample-data-1.png" width="60%" style="display: block; margin: auto;" /&gt;

---

class: middle, center

# Standard 2×2 Table Format

| | Disease | No Disease | Total |
|---|---:|---:|---:|
| **Exposed** | 30 (a) | 70 (b) | 100 (a+b) |
| **Not Exposed** | 20 (c) | 80 (d) | 100 (c+d) |
| **Total** | 50 (a+c) | 150 (b+d) | 200 (N) |

**Cell Labels:** Use a, b, c, d for formulas

---

class: middle

# Understanding Odds

.pull-left[
**Formula:**
`$$\text{Odds} = \frac{P(\text{Event})}{P(\text{No Event})}$$`

**Exposed Group:**
- P(Disease) = 30/100 = 0.3
- P(No Disease) = 70/100 = 0.7  
- **Odds = 30/70 = 0.43**
]

.pull-right[
**Non-Exposed Group:**
- P(Disease) = 20/100 = 0.2
- P(No Disease) = 80/100 = 0.8
- **Odds = 20/80 = 0.25**

**Shortcut:** Odds = a/b and c/d
]

---

class: middle

# Odds Ratio (OR) Calculation



.pull-left[
**Formula:**
`$$OR = \frac{\text{Odds}_{\text{exposed}}}{\text{Odds}_{\text{unexposed}}} = \frac{a \times d}{b \times c}$$`

**Our Data:**
`$$OR = \frac{30 \times 80}{70 \times 20} = \frac{2400}{1400} = 1.71$$`
]

.pull-right[
**95% Confidence Interval:**
`$$e^{\ln(OR) \pm 1.96\sqrt{\frac{1}{a}+\frac{1}{b}+\frac{1}{c}+\frac{1}{d}}}$$`

**Result:** (0.89, 3.29)

**Interpretation:** Exposed group has 1.71 times the odds of disease
]

---

class: middle

# Risk Ratio (RR) Calculation



.pull-left[
**Formula:**
`$$RR = \frac{\text{Risk}_{\text{exposed}}}{\text{Risk}_{\text{unexposed}}}$$`

**Calculations:**
- Risk_exposed = 30/100 = 0.3
- Risk_unexposed = 20/100 = 0.2  
- **RR = 0.3/0.2 = 1.5**
]

.pull-right[
**95% CI:** (0.92, 2.46)

**Interpretation:** Exposed group has 1.5 times the risk

**Note:** Only use with cohort studies/RCTs!
]

---

class: middle

# Risk Difference &amp; NNT



.pull-left[
**Risk Difference (RD):**
`$$RD = \text{Risk}_{\text{exposed}} - \text{Risk}_{\text{unexposed}}$$`
`$$RD = 0.3 - 0.2 = 0.1$$`

**Interpretation:** 10% absolute increase in risk
]

.pull-right[
**Number Needed to Harm (NNH):**
`$$NNH = \frac{1}{|RD|} = \frac{1}{|0.1|} = 10$$`

**Interpretation:** For every 10 people exposed, 1 additional person gets disease

**Clinical Relevance:** Practical impact measure
]

---

class: middle

# Interpretation Guide

.pull-left[
**Odds Ratio (OR)**
- OR = 1: No association
- OR &gt; 1: Increased odds  
- OR &lt; 1: Decreased odds (protective)

**Risk Ratio (RR)**  
- RR = 1: No association
- RR &gt; 1: Increased risk
- RR &lt; 1: Decreased risk (protective)
]

.pull-right[
**Risk Difference (RD)**
- RD = 0: No difference
- RD &gt; 0: Increased absolute risk
- RD &lt; 0: Decreased absolute risk

**Statistical Significance**
- **For ratios:** 95% CI excludes 1
- **For differences:** 95% CI excludes 0
]

---

class: middle, center

# Important Caveats

---

class: middle

# Critical Points to Remember

.pull-left[
**When CI Includes 1 (for ratios):**
- Result NOT statistically significant
- "No effect" is plausible
- Be cautious interpreting

**Risk Ratios vs Odds Ratios:**
- RR only from population samples
- OR from case-control studies
- OR approximates RR for rare diseases
]

.pull-right[
**Subgroup Analysis Warning:**
- Seems clinically relevant
- **Major source of false positives**
- Better for hypothesis generation
- Avoid definitive conclusions

**Multiple Testing Problem:**
- 20 tests → expect 1 false positive
- α = 0.05 means 5% false positive rate
]

---

class: middle

# Multiple Testing Reality Check

.pull-left[
.center[

Table: Example: Multiple Comparisons Problem

|Variable  |P_value |Significant |
|:---------|:-------|:-----------|
|Age       |0.042*  |Yes         |
|Gender    |0.156   |No          |
|BMI       |0.678   |No          |
|Smoking   |0.023*  |Yes         |
|Exercise  |0.891   |No          |
|Diet      |0.034*  |Yes         |
|Sleep     |0.456   |No          |
|Stress    |0.012*  |Yes         |
|Education |0.789   |No          |
|Income    |0.067   |No          |
|Location  |0.445   |No          |
|Season    |0.028*  |Yes         |
]
]

.pull-right[
**The Problem:**
- 12 tests performed
- 5 "significant" results  
- Expected by chance: 12 × 0.05 ~ 1

**Reality Check:**
- Most are likely false positives due to nearness to 0.05
- Need correction for multiple testing
- Better for hypothesis generation
]

---

class: middle, center, inverse

# Part 2: Study Designs &amp; Biases

---

class: middle

# Key Concepts Review

.pull-left[
**Internal Validity**
- Results true for study participants
- Free from bias and confounding  
- Cause-and-effect relationships
- High control = high internal validity
]

.pull-right[
**External Validity (Generalizability)**
- Results apply to other populations
- Relevant to YOUR patients
- Real-world applicability
- Often trade-off with internal validity
]

---

class: middle, center

# Types of Biases

---

class: middle

# Design &amp; Hidden Variable Biases

.pull-left[
**Selection Bias**
- Non-random group assignment
- Systematic baseline differences
- *Example:* Healthier patients get new treatment
- *Solution:* Randomization

**Observer-Expectancy Bias**  
- Researcher expectations influence observations
- *Example:* Doctor expects drug to work
- *Solution:* Blinding
]

.pull-right[
**Effect Modification**
- Effect varies by third variable
- *Example:* Drug works in boys, not girls
- *Solution:* Stratified analysis

**Confounding**
- Third variable causes apparent association
- *Example:* Coffee → cancer (but smoking is real cause)
- *Solutions:* Randomization, regression analysis
]

---

class: middle

# Information (Measurement) Biases

.pull-left[
**Recall Bias**
- Diseased patients remember exposures better
- *Example:* Birth defect mothers recall medications
- *Solutions:* Objective data, medical records

**Procedure Bias**
- Systematic differences in data collection
- *Example:* More time spent with treatment group
- *Solutions:* Standardized protocols, blinding
]

.pull-right[
**Instrument Bias**
- Faulty or inconsistent measurement tools
- *Example:* Miscalibrated BP cuff, unclear survey
- *Solutions:* Calibration, validation, reliability testing
]

---

class: middle

# Time &amp; Completion Biases

.pull-left[
**Lead-Time Bias**
- Earlier detection ≠ longer survival
- *Example:* Screening finds cancer 5 years earlier, same death age
- *Solution:* Measure from symptom onset

**Attrition Bias**
- Systematic withdrawal related to outcome
- *Example:* Side effects cause dropout
- *Solutions:* Intention-to-treat analysis
]

.pull-right[
**Loss-to-Follow-Up**
- Participants don't return for visits
- Can be random or systematic
- *Solutions:* Good contact maintenance, incentives
- **Concern if &gt;20% loss**
]

---

class: middle, center

# The pyramid of evidence is a hierarchy

&lt;img src="figs/evidence_pyramid.jpg" width="50%" /&gt;

--- 

class: middle, center

# Experimental Trials

---

class: middle, center

# Randomized control trial is in the name

&lt;img src="figs/randomized_control.png" width="90%" /&gt;

---

class: middle

# Randomized control - gold standard

--

- This is widely considered the gold standard for clinical evidence
--
&lt;br&gt;&lt;br&gt;
- Question: __Primary__ purpose of randomization?
--

- Answer: To eliminate __selection bias__
  - Selection bias (at the time of randomization) is eliminated if randomization is technically correct
--

&lt;br&gt;&lt;br&gt;
- Question: Secondary goal of randomization?
--

- Answer: To help with confounding
  - Confounders are not necessarily eliminated even with perfect technical execution
--
&lt;br&gt;&lt;br&gt;
- Can use relative risk because investigator knows prevalence of disease and prior exposures

---

class: middle

# Randomized control - limitations

- Can still technically suffer from selection bias (as defined by epidemiologists). Why?
--
&lt;br&gt;
  - Loss to follow up
--
&lt;br&gt;&lt;br&gt;
- They may or may not externalize well
--
&lt;br&gt;&lt;br&gt;
- There are may ethical concerns in pediatrics
--
&lt;br&gt;&lt;br&gt;
- They are ridiculously expensive

---

class: middle

# Crossover trial - groups switch

&lt;img src="figs/crossover.png" width="100%" /&gt;

&lt;br&gt;
- This post hoc analysis is overly simplified for real life
 
- This understanding is sufficient for boards
 
- Includes initial randomization

- Also, confounders reduced because a patient can serve as their own control

---

class: middle, center

# Observational Studies

---

class: middle

# Prospective cohorts - into the future

&lt;img src="figs/prospective_cohort.png" width="100%" /&gt;


---


class: middle

# Retrospective cohorts - from the past

&lt;img src="figs/retrospective_cohort.png" width="100%" /&gt;


---

class: middle

# Cohorts form the next level of evidence
 
--

- Can still use relative risk because investigator knows prevalence of exposure and disease
- Subjects vary by exposure status
- Can calculate incidence
--
&lt;br&gt;&lt;br&gt;
- __Selection bias__ is the biggest problem
  - Investigator has infinite control over inclusion
--
&lt;br&gt;&lt;br&gt;
- Other Prospective biases
  - Attrition - people leave the trial intentionally
  - Loss-to-follow up - people just stop showing up
  - Confounding - baseline characteristics or ongoing characteristics are difference
  - Hawthorne - people act differently once observed
--
&lt;br&gt;&lt;br&gt;
- Retrospective bias
  - Information bias

---

class: middle, center

# Case-control trials measure chance of exposure given disease

&lt;img src="figs/case_control.png" width="100%" /&gt;

---

class: middle

# Case-control forms the next level down from cohorts
--

- Must use odds ratio because investigator does not know prevalence of disease
--
&lt;br&gt;&lt;br&gt;
- Subjects grouped by cases and controls
  - Measure __odds of exposure__ in case and control groups
--
&lt;br&gt;&lt;br&gt;
- Significantly improved power and decreased resource requirements compared to cohorts 
  - Due to cases being selected at out set
--
&lt;br&gt;&lt;br&gt;
- __Selection and Recall biases__ are the biggest problem
  - Selecting appropriate controls is __highly__ non-trivial
  - Sick people remember exposures (e.g. Melanoma patients stew about their sunburns)
--
&lt;br&gt;&lt;br&gt;
- Also common
   - Information biases
--
&lt;br&gt;&lt;br&gt;
- __Cannot calculate incidence or prevalence__

---

class: middle, center

# Cross-sectional trials measure exposure and disease simultaneously

&lt;img src="figs/cross_sectional.png" width="100%" /&gt;

---

class: middle

# Cross-sectional study - next level

--

- __Quick, cheap, and easy__
  - Typically this is a starting point
--
&lt;br&gt;&lt;br&gt;
- Can establish prevalence of disease
--
&lt;br&gt;&lt;br&gt;
- Must use chi-squared or correlation for statistical test
--
&lt;br&gt;&lt;br&gt;
- Subjects can be grouped by exposure and diease in to the 2x2 contingency
--
&lt;br&gt;&lt;br&gt;
- __Cannot establish causation__
--
&lt;br&gt;&lt;br&gt;
- Cannot calculate risk metrics
 
---

class: middle, center

# Questions?

### Thank you for your attention!

**Remember:** Evidence-based medicine combines the best research evidence with clinical expertise and patient values.

---
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create({
"highlightStyle": "github",
"highlightLines": true,
"countIncrementalSlides": true,
"ratio": "16:9"
});
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
// add `data-at-shortcutkeys` attribute to <body> to resolve conflicts with JAWS
// screen reader (see PR #262)
(function(d) {
  let res = {};
  d.querySelectorAll('.remark-help-content table tr').forEach(tr => {
    const t = tr.querySelector('td:nth-child(2)').innerText;
    tr.querySelectorAll('td:first-child .key').forEach(key => {
      const k = key.innerText;
      if (/^[a-z]$/.test(k)) res[k] = t;  // must be a single letter (key)
    });
  });
  d.body.setAttribute('data-at-shortcutkeys', JSON.stringify(res));
})(document);
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();
// adds .remark-code-has-line-highlighted class to <pre> parent elements
// of code chunks containing highlighted lines with class .remark-code-line-highlighted
(function(d) {
  const hlines = d.querySelectorAll('.remark-code-line-highlighted');
  const preParents = [];
  const findPreParent = function(line, p = 0) {
    if (p > 1) return null; // traverse up no further than grandparent
    const el = line.parentElement;
    return el.tagName === "PRE" ? el : findPreParent(el, ++p);
  };

  for (let line of hlines) {
    let pre = findPreParent(line);
    if (pre && !preParents.includes(pre)) preParents.push(pre);
  }
  preParents.forEach(p => p.classList.add("remark-code-has-line-highlighted"));
})(document);</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
